Recombinant human IL-21 protein

IL-21, also known as Interleukin-21, is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses. It has broad immunoregulatory activity and can modulate both humoral and cell-mediated responses. It is important in the regulation of haematopoiesis and immune responses, and can influence lymphocyte development. It is produced by activated T cell, and it influences proliferation of T and B cells and cytolytic activity of natural killer cells. It may be a critical factor in the control of persistent viral infections. It has a potential predicating significance for survival Time in patients in the development of sporadic CRC. It binds to the IL-21R and can activate janus kinase JAK1, JAK3, STAT1, and STAT3 in EDgamma-16 cells. Recombinant human IL-21, was expressed in E. coli and purified by using conventional chromatography techniques.

Product Specifications

Specifications

Human IL-21 stimulates IFN-g secretion of the NK-92 human natural killer cells. The ED50 range ≤4 ng/mL.

Product Name Alternative

Interleukin-21 isoform 1, CVID11, IL-21, Za11

Expression System

E.coli

Antigen Species

Human

Tag

Non-Tagged

Applications

SDS-PAGE, Bioactivity

Concentration

0.25 mg/mL (determined by absorbance at 280 nm)

Endotoxin

< 1 EU per 1ug of protein (determined by LAL method)

Purity

> 95% by SDS-PAGE

Bioactivity

The activity is determined by the IFN-g ELISA in a using NK-92 human natural killer cells. The ED50 range ≤4 ng/mL.

Molecular Weight

15.5 kDa (134aa) confirmed by MALDI-TOF

Additionnal Information

IL21, ATGP3861-10 µg, ATGP3861-20 µg, ATGP3861-50 µg, ATGP3861-100 µg, ATGP3861-250 µg, ATGP3861-500 µg, ATGP3861-1 mg, ATGP3861-10, ATGP3861-20, ATGP3861-50, ATGP3861-100, ATGP3861-250, ATGP3861-500, ATGP3861-1

References & Citations

Gui G., et al. (2017) Clin Immunol. 183:266-272.; ; Parrish-Novak J., et al. (2000) Nature. 408 (6808) :57-63.

Other References

Park SJ, et al. A general toxicity and biodistribution study of human natural killer cells by single or repeated intravenous dose in severe combined immune deficient mice. (Toxicol Res. 2022) {https://doi.org/10.1007/s43188-022-00138-0}